Hepatitis c virus-specific t-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis

Hepatitis C virus (HCV)‐specific immune effector responses can cause liver damage in chronic infection. Hepatic stellate cells (HSC) are the main effectors of liver fibrosis. TGFβ, produced by HCV‐specific CD8+ T cells, is a key regulatory cytokine modulating HCV‐specific effector T cells. Here we s...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 56; no. 6; pp. 2094 - 2105
Main Authors Li, Shaoyong, Vriend, Lianne E.M., Nasser, Imad A., Popov, Yury, Afdhal, Nezam H., Koziel, Margaret J., Schuppan, Detlef, Exley, Mark A., Alatrakchi, Nadia
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2012
Wiley
Wolters Kluwer Health, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hepatitis C virus (HCV)‐specific immune effector responses can cause liver damage in chronic infection. Hepatic stellate cells (HSC) are the main effectors of liver fibrosis. TGFβ, produced by HCV‐specific CD8+ T cells, is a key regulatory cytokine modulating HCV‐specific effector T cells. Here we studied TGFβ as well as other factors produced by HCV‐specific intrahepatic lymphocytes (IHL) and peripheral blood cells in hepatic inflammation and fibrogenesis. This was a cross‐sectional study of two well‐defined groups of HCV‐infected subjects with slow (≤0.1 Metavir units/year, n = 13) or rapid (n = 6) liver fibrosis progression. HCV‐specific T‐cell responses were studied using interferon‐gamma (IFNγ)‐ELISpot ±monoclonal antibodies (mAbs) blocking regulatory cytokines, along with multiplex, enzyme‐linked immunosorbent assay (ELISA) and multiparameter fluorescence‐activated cell sorting (FACS). The effects of IHL stimulated with HCV‐core peptides on HSC expression of profibrotic and fibrolytic genes were determined. Blocking regulatory cytokines significantly raised detection of HCV‐specific effector (IFNγ) responses only in slow fibrosis progressors, both in the periphery (P = 0.003) and liver (P = 0.01). Regulatory cytokine blockade revealed HCV‐specific IFNγ responses strongly correlated with HCV‐specific TGFβ, measured before blockade (R = 0.84, P = 0.0003), with only a trend to correlation with HCV‐specific IL‐10. HCV‐specific TGFβ was produced by CD8 and CD4 T cells. HCV‐specific TGFβ, not interleukin (IL)‐10, inversely correlated with liver inflammation (R = −0.63, P = 0.008) and, unexpectedly, fibrosis (R = −0.46, P = 0.05). In addition, supernatants from HCV‐stimulated IHL of slow progressors specifically increased fibrolytic gene expression in HSC and treatment with anti‐TGFβ mAb abrogated such expression. Conclusion: Although TGFβ is considered a major profibrogenic cytokine, local production of TGFβ by HCV‐specific T cells appeared to have a protective role in HCV‐infected liver, together with other T‐cell‐derived factors, ameliorating HCV liver disease progression. (HEPATOLOGY 2012;56:2094–2105)
Bibliography:istex:E94150CF090AD6FC5C7B44C178AA9315963D0616
The protocol was reviewed and approved by the Investigational Review Board of Beth Israel Deaconess Medical Center and all subjects gave informed consent for the collection of specimens.
Potential conflict of interest: Nothing to report.
Financial support: U19 AI066313 to N.A., M.E., and D.S., R01 DK066917 and R21 CA143748 to M.E., China Scholarship Council to S.L., and U01 AI068636 to N.A.
ArticleID:HEP25951
Present address for M.J. Koziel: Vertex Pharmaceuticals, Cambridge, MA.
China Scholarship Council - No. U19 AI066313; No. R01 DK066917; No. R21 CA143748; No. U01 AI068636
These authors participated equally in this study.
ark:/67375/WNG-R96SGLN3-9
fax: 617‐667‐8154
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
the first two authors SL and LV participated equally to the MS
present address: Vertex Pharmaceuticals, Cambridge, MA
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.25951